61 studies found for:    burzynski
Show Display Options
Rank Status Study
21 Unknown  Antineoplaston Therapy in Treating Children With Rhabdoid Tumor of the Central Nervous System
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
22 Withdrawn Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy
Conditions: Merkel Cell Carcinoma;   Islet Cell Carcinoma;   Neuroendocrine Carcinoma;   Pituitary Tumor
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1;   Procedure: alternative product therapy;   Procedure: biological  therapy;   Procedure: biologically based therapies;   Procedure: cancer prevention intervention;   Procedure: complementary and alternative therapy;   Procedure: differentiation therapy
23 Unknown  Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer
Condition: Head and Neck Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
24 Unknown  Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
25 Terminated Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus
Condition: Esophageal Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
26 Completed Antineoplaston Therapy in Treating Patients With Stage IV Melanoma
Condition: Melanoma (Skin)
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
27 Unknown  Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
28 Unknown  Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer
Condition: Lung Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
29 Unknown  Antineoplaston Therapy in Treating Women With Stage IV Breast Cancer
Condition: Breast Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
30 Unknown  Antineoplaston Therapy in Treating Patients With Stomach Cancer
Condition: Gastric Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
31 Unknown  Antineoplaston Therapy in Treating Patients With Metastatic or Unresectable Colon Cancer
Condition: Colorectal Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
32 Unknown  Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva
Conditions: Cervical Cancer;   Vulvar Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
33 Unknown  Antineoplaston Therapy in Treating Patients With Stage IV Bladder Cancer or Stage IV Newly Diagnosed, Incurable Bladder Cancer
Condition: Bladder Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
34 Withdrawn Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Condition: Primary Central Nervous System Lymphoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1;   Procedure: alternative product therapy;   Procedure: biological  therapy;   Procedure: biologically based therapies;   Procedure: cancer prevention intervention;   Procedure: complementary and alternative therapy;   Procedure: differentiation therapy
35 Unknown  Antineoplaston Therapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
36 Withdrawn Antineoplaston Therapy in Treating Patients With Colon Cancer
Conditions: Stage IV Colon Cancer;   Recurrent Colon Cancer;   Adenocarcinoma of the Colon
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1;   Procedure: alternative product therapy;   Procedure: biological  therapy;   Procedure: biologically based therapies;   Procedure: cancer prevention intervention;   Procedure: complementary and alternative therapy;   Procedure: differentiation therapy
37 Unknown  Antineoplaston Therapy in Treating Children With Primitive Neuroectodermal Tumors
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
38 Unknown  Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia
Conditions: Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
39 Unknown  Antineoplaston Therapy in Treating Patients With Cancer of the Small Intestine
Condition: Small Intestine Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
40 Withdrawn Antineoplaston Therapy in Treating Women With Advanced Breast Cancer
Conditions: Stage IV Breast Cancer;   Recurrent Breast Cancer
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1;   Procedure: alternative product therapy;   Procedure: biological  therapy;   Procedure: biologically based therapies;   Procedure: cancer prevention intervention;   Procedure: complementary and alternative therapy;   Procedure: differentiation therapy

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years